Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
APLS 
Apellis Pharmaceuticals Inc (APLS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/28/2025: APLS (3-star) is a STRONG-BUY. BUY since 5 days. Simulated Profits (6.79%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
22 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $38.06
1 Year Target Price $38.06
| 10 | Strong Buy |
| 4 | Buy |
| 8 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 80.71% | Avg. Invested days 56 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.80B USD | Price to earnings Ratio - | 1Y Target Price 38.06 |
Price to earnings Ratio - | 1Y Target Price 38.06 | ||
Volume (30-day avg) 22 | Beta 0.68 | 52 Weeks Range 16.10 - 35.72 | Updated Date 10/28/2025 |
52 Weeks Range 16.10 - 35.72 | Updated Date 10/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.85 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -30.24% | Operating Margin (TTM) -18.65% |
Management Effectiveness
Return on Assets (TTM) -13.77% | Return on Equity (TTM) -108.49% |
Valuation
Trailing PE - | Forward PE 46.3 | Enterprise Value 3018290820 | Price to Sales(TTM) 5.03 |
Enterprise Value 3018290820 | Price to Sales(TTM) 5.03 | ||
Enterprise Value to Revenue 4 | Enterprise Value to EBITDA -12.12 | Shares Outstanding 126289910 | Shares Floating 78428560 |
Shares Outstanding 126289910 | Shares Floating 78428560 | ||
Percent Insiders 13.67 | Percent Institutions 105.8 |
Upturn AI SWOT
Apellis Pharmaceuticals Inc
Company Overview
History and Background
Apellis Pharmaceuticals, Inc. was founded in 2009. It is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic compounds to treat disease through the complement system.
Core Business Areas
- Pegcetacoplan (Empaveli/Aspaveli): Treatment for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder.
- Pegcetacoplan (Syfovre): Treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a leading cause of blindness.
Leadership and Structure
The company is led by a management team with expertise in drug development and commercialization. The organizational structure includes research, development, commercial, and administrative functions.
Top Products and Market Share
Key Offerings
- Empaveli/Aspaveli (pegcetacoplan): A C3 complement inhibitor used to treat PNH. Competitors include Alexion Pharmaceuticals (acquired by AstraZeneca) with Soliris and Ultomiris. Market share data is difficult to determine precisely as the overall PNH market size changes. The company reports revenue from this product line in their quarterly and annual reports. Revenue in 2023 was $396.3 million, up 55% from the previous year.
- Syfovre (pegcetacoplan): A C3 complement inhibitor used to treat Geographic Atrophy (GA). Competitors include Iveric Bio, now part of Astellas Pharma (ALPMY), who have launched IZERVAY. Market share is evolving in a highly competitive space. Syfovre Revenue in 2023 was $356.9 million.
Market Dynamics
Industry Overview
The biopharmaceutical industry is competitive and rapidly evolving, driven by scientific innovation and regulatory changes. Companies are focused on developing innovative therapies for unmet medical needs.
Positioning
Apellis is positioned as a company focused on complement-targeted therapies, with a leading presence in the PNH and GA markets. Their competitive advantage lies in their expertise in complement biology and their innovative drug candidates.
Total Addressable Market (TAM)
The total addressable market for GA and PNH treatments is significant, estimated in the billions of dollars annually. Apellis is positioned to capture a substantial portion of this market with their products Syfovre and Empaveli.
Upturn SWOT Analysis
Strengths
- Innovative drug candidates
- Strong expertise in complement biology
- Established presence in PNH market
- First approved therapy for GA
- Experienced management team
Weaknesses
- Reliance on a limited number of products
- Commercial execution challenges for Syfovre
- Dependence on regulatory approvals
- Potential for competition from biosimilars
- Potential safety issues
Opportunities
- Expansion into new indications
- Partnerships and collaborations
- Geographic expansion
- Advancements in complement biology research
- Increasing prevalence of GA and PNH
Threats
- Competition from established pharmaceutical companies
- Regulatory challenges
- Adverse safety events
- Pricing pressures
- Intellectual property disputes
Competitors and Market Share
Key Competitors
- AZN
- ALPMY
Competitive Landscape
Apellis competes with established pharmaceutical companies in the PNH and GA markets. Their advantages include their innovative drug candidates and expertise in complement biology. Disadvantages include their limited product portfolio and smaller scale.
Growth Trajectory and Initiatives
Historical Growth: Apellis has experienced substantial revenue growth since the launch of its products.
Future Projections: Analyst estimates project continued revenue growth for Apellis, driven by increased adoption of Syfovre and Empaveli.
Recent Initiatives: Recent initiatives include expanding the market access for Syfovre and Empaveli, and advancing their pipeline of complement-targeted therapies.
Summary
Apellis Pharmaceuticals is a growing biopharmaceutical company focused on complement-targeted therapies. The company has shown significant revenue growth with key drugs for PNH and GA. Although revenue has grown, the company faces commercial challenges and competition. Close monitoring of financial performance, and competitive pressures will be important.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Apellis Pharmaceuticals Inc. Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is estimated based on available information and may not be precise. The AI-based rating is based on an analysis of publicly available information and is not a guarantee of future performance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Apellis Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2017-11-09 | Co-Founder, President, CEO & Director Dr. Cedric Francois M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 705 | Website https://apellis.com |
Full time employees 705 | Website https://apellis.com | ||
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.